ADC Therapeutics (ADCT) EBT Margin (2021 - 2026)
ADC Therapeutics (ADCT) posted quarterly EBT Margin of 158.11% for Q1 2026, up 877.0% year-on-year from 16.18% in Q1 2025, and up 36.6% on a QoQ basis from 249.38% in Q3 2025.
ADC Therapeutics (ADCT) EBT Margin (2021 - 2026) Analysis & Trends
ADC Therapeutics (ADCT) has reported EBT Margin for 6 consecutive years, with 158.11% the latest figure, recorded in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - | - |
| 2 | Nanobiotix | 1,908.96 Bn | 1,908.90 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 474.03 Bn | 469.24 Bn | 1.35 Bn | 17.13% |
| 5 | Vertex Pharmaceuticals | 122.13 Bn | 114.88 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 70.09 Bn | 61.34 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.96 Bn | 50.77 Bn | 1.41 Bn | 34.77% |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn | 18.99% |
| 10 | ADC Therapeutics | 174.18 Mn | -56.83 Mn | 17.38 Mn | -158.11% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -158.11% |
| Sep 30, 2025 | -249.38% |
| Jun 30, 2025 | -294.03% |
| Mar 31, 2025 | -166.88% |
| Sep 30, 2024 | -236.24% |
| Jun 30, 2024 | -205.13% |
| Mar 31, 2024 | -253.70% |
| Sep 30, 2023 | -313.27% |
| Jun 30, 2023 | -273.30% |
| Mar 31, 2023 | -314.28% |
| Sep 30, 2022 | -67.24% |
| Jun 30, 2022 | -377.77% |
| Mar 31, 2022 | -38.35% |
| Sep 30, 2021 | -543.12% |
| Jun 30, 2021 | -1,923.64% |